Skip to main content

Table 1 Baseline characteristics

From: Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial

Characteristic

 

N = 50

Age (years)

Median (IQR)

66.0 (57.8–68.0)

Sex

Male

42 (84.0%)

Female

8 (16.0%)

Smoking history

Ever

35 (70.0%)

Never

15 (30.0%)

Stage

IIB

4 (8.0%)

IIIA

24 (48.0%)

IIIB

16 (32.0%)

IIIC

6 (12.0%)

PD-L1 expression

<1%

11 (22.0%)

1–49%

8 (16.0%)

>49%

5 (10.0%)

Unknown

26 (52.0%)

Histopathology

Squamous cell carcinoma

32 (64.0%)

Adenocarcinoma

9 (18.0%)

NSCLC-NOS

9 (18.0%)

Treatment cycle

1

2 (4.0%)

2

18 (36.0%)

3

15 (30.0%)

4

15 (30.0%)

  1. IQR interquartile range, NSCLC-NOS non-small-cell lung cancer-not otherwise specified